Dr. Guy E. Brannon, M.D.
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 129
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
LA license 022555 -
Specialist
LA license 022555
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Brentwood Acquisition-Shreveport Inc (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 432
- Patients’ average age
- 55
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 266 | 81 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 173 | 65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 45 | 33 |
| Hospital discharge day management, more than 30 minutes | 39 | 32 |
| New patient office or other outpatient visit, 30-44 minutes | 15 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 95 payments worth $1,745 in total to this clinician.
| Food and Beverage | $1,741 |
|---|---|
| Education | $4.55 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Feb 3, 2025 | Education in-kind | $4.55 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 3 companies. The companies reported $614,403 in research payments for these studies, mostly to the institutions running them.
- A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
AbbVie Inc. · Terminated · NCT05443724 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
AbbVie Inc. · Completed · NCT06605599 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie Inc. · Recruiting · NCT07276997 - Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder
AbbVie Inc. - A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
AbbVie Inc. · Completed · NCT05227690 - ITI-007-451
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)
AbbVie Inc. - Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
AbbVie Inc. · Active, not recruiting · NCT07220460 - M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.